Investors wanted a near-term plan but got 2030 targets instead, while CagriSema missed against Zepbound and Morgan Stanley downgraded the stock over the semaglutide patent cliff.
Recap by typeshit. Full story at TradingView.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
11:37
A 63 year old creator walks through six months on tirzepatide and a 48 pound drop, sharing a personal account of the experience.
Philstar Life looks at famous names linked to Ozempic for weight loss. Only a search title came through, so details are thin until you open the source.
An international food and agribusiness expert links growing interest in fibre to the spread of GLP-1 drugs. Details are thin beyond the claim itself.
A Medscape opinion roundup asks whether microdosing tirzepatide carries too much risk and whether surgery still matters, plus why sweet-and-salty snacks hook us.
King Khalid University researchers also report substantial weight regain after people stop the drug, and flag gallbladder and retinopathy signals worth watching.
Loading…